TriangleNCT05551117 · OUTCOME
Part 2: Median DoR Per Investigator Assessment of RECIST 1.1 Criteria
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
What was measured
The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented progressive disease (PD) or death from any cause, whichever occurs first.
Analysis population: No participants in Part 2 of the study had a complete or partial response to study treatment.
Groups in this outcome
Part 2
vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks
| Group | Source count |
|---|---|
| Part 2 | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented progressive disease (PD) or death from any cause, whichever occurs first.
- groups
- description
- vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks
- id
- OG000
- title
- Part 2
- population Description
- No participants in Part 2 of the study had a complete or partial response to study treatment.
- reporting Status
- POSTED
- time Frame
- Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
- title
- Part 2: Median DoR Per Investigator Assessment of RECIST 1.1 Criteria
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice